Clinical trials: Antiviral Treatment
Chronic Hepatitis C Infection
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are…
- Trial name
- SWITCH-1 (NCT02583685)
- Testing
- PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Humanity and Health Research Centre
Cytomegalovirus Retinitis, HIV Infections
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral…
- Trial name
- NCT00002355
- Testing
- Fomivirsen sodium
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
HIV Infections, HBV Coinfection
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple…
- Trial name
- BI-LIGHT (NCT06338826)
- Testing
- TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI, Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
- Volunteers
- 140 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19
Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure
A recent report in Physiolological Reviews proposed that the endogenous protease plasmin acts on SARS-CoV-2 by cleaving a newly inserted furin site in the S protein portion of the virus resulting in increased infectivity and…
- Trial name
- TXACOVIDPREV (NCT04550338)
- Testing
- Tranexamic acid
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV Infections
Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to add PMPA Prodrug (a new anti-HIV drug) to an anti-HIV drug combination taken by patients who have taken anti-HIV drugs in the past.
- Trial name
- NCT00002415
- Testing
- Tenofovir disoproxil fumarate
- Where
- 24 sites in United States
- Volunteers
- 175 people
- Sponsor
- Gilead Sciences
HIV Infections
Naïve HIV POC Monotherapy Trial
The primary objective of the trial is: to evaluate the change from baseline in plasma viral load with placebo and one of up to 4 dose regimens of RDEA806.
- Trial name
- NCT00617526
- Testing
- RDEA806 400 mg, RDEA806 1000 mg, RDEA806 600 mg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Ardea Biosciences, Inc.
Astrocytoma, Grade IV, Giant Cell Glioblastoma
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide
- Trial name
- CYNK001GBM01 (NCT04489420)
- Testing
- CYNK001-IV, CYNK001-IT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Celularity Incorporated
Acute-on-Chronic Liver Failure (ACLF), hepatitisB
The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients
This is an observational study. This study mainly explores the dynamic changes of HBV RNA and HBcrAg during the treatment of HBV-ACLF, as well as the safety of entecavir (ETV), tenofovir alafenamide (TAF) and tenofovir…
- Conditions
- Acute-on-Chronic Liver Failure (ACLF), hepatitisB, Treatment
- Trial name
- NCT07815418
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Tongji Hospital
HIV
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/…
- Trial name
- NCT01620944
- Testing
- Atazanavir, Ritonavir, Lamivudine
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04059198
- Testing
- Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF)
- Where
- 2 sites in Hong Kong
- Volunteers
- 5 people
- Sponsor
- F-star Therapeutics, Inc.
Hepatitis C, Chronic
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV)…
- Trial name
- NCT01849562
- Testing
- Sovaprevir, ACH-3102, Ribavirin
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Hepatitis C
Long-Term Therapy With Ribavirin for Chronic Hepatitis C
Chronic hepatitis C is a disease of the liver caused by the hepatitis C virus. The disease can be serious and even fatal. Approximately 25% of patients with chronic hepatitis C will develop cirrhosis and some of these patients…
- Trial name
- NCT00001854
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Influenza
Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study
The purpose of this study is to determine whether Chinese medicinal herbs are effective and safe for treating novel influenza A (H1N1) infection.
- Trial name
- NCT00935194
- Testing
- oseltamivir, blank, chinese medicinal herbs
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Capital Medical University
Hepatitis C Virus Infection
Implementing HCV Treatment for High-risk Populations in Austin, Texas
Highly-effective, pan-genotypic direct acting antivirals (DAAs) have made elimination of hepatitis C virus (HCV) a real possibility.
- Trial name
- NCT05460130
- Testing
- Simplified Hepatitis C Virus (HCV) Treatment Protocol
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Texas at Austin
Chronic Hepatitis C Infection
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
Objectives: 1) To evaluate la proportion of hepatitic C virus (HCV)-monoinfected patients who show sustained virologic response (SVR) to treatment including direct-acting antivirals (DAAs) in the clinical practice in clinical…
- Trial name
- FPSMON201401 (NCT02333292)
- Testing
- Telaprevir, Boceprevir, Sofosbuvir
- Where
- Spain
- Volunteers
- 1,128 people
- Sponsor
- Valme University Hospital
Pharmacological Action
Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2.
- Trial name
- BARI-COVID (NCT04320277)
- Testing
- Baricitinib
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Hospital of Prato
HBeAg Positive Chronic Hepatitis B Infection
Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection
During hepatitis B virus(HBV) infection host immune plays important role.Recently there are many different antiviral therapy methods.Different antiviral therapy methods showed different effector.In order to investigate whether…
- Trial name
- NCT01480492
- Testing
- Telbivudine
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Cz Li
Chronic Genotype 1a or 1b HCV Infection
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects…
- Trial name
- NCT01434498
- Testing
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule
- Where
- 50 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS
To find oral doses of FIAC (a pyrimidine nucleoside analog) that are effective in treating cytomegalovirus (CMV) viremia in HIV-infected immunocompromised patients; to determine tolerance and safety of FIAC in this patient…
- Trial name
- NCT00000981
- Testing
- Fiacitabine
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3
To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
- Trial name
- NCT00000625
- Testing
- Zidovudine, Zalcitabine, Didanosine
- Where
- 58 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)